Lixte Biotechnology Holdings Information, Including Revenue, Investors, Funding, Competitors & Key Metrics

Lixte Biotechnology Holdings, Inc. is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways

Company Highlights
Year Founded

2006

icon-altEmployees

5

Location (HQ)

USA

Since Last Funding

8 days

Monthly Website Visitors

1.7K

icon-altTotal Investment Amt

$12M

Last Funding Round

Post Ipo Equity

icon-altYoY Headcount Growth

-16.39%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Biotechnology Research

Biotechnology

Health Care

Pharmaceutical

Oncology